JP2015528454A - 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用 - Google Patents

眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用 Download PDF

Info

Publication number
JP2015528454A
JP2015528454A JP2015529009A JP2015529009A JP2015528454A JP 2015528454 A JP2015528454 A JP 2015528454A JP 2015529009 A JP2015529009 A JP 2015529009A JP 2015529009 A JP2015529009 A JP 2015529009A JP 2015528454 A JP2015528454 A JP 2015528454A
Authority
JP
Japan
Prior art keywords
vegf antagonist
weeks
treatment
antibody vegf
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015529009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015528454A5 (OSRAM
Inventor
オズボーン，アーロン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2015528454A publication Critical patent/JP2015528454A/ja
Publication of JP2015528454A5 publication Critical patent/JP2015528454A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/008—Methods or devices for eye surgery using laser
    • A61F9/00821—Methods or devices for eye surgery using laser for coagulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/178—Lectin superfamily, e.g. selectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2015529009A 2012-08-28 2013-08-28 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用 Pending JP2015528454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261693913P 2012-08-28 2012-08-28
US61/693,913 2012-08-28
PCT/EP2013/067846 WO2014033184A1 (en) 2012-08-28 2013-08-28 Use of a vegf antagonist in treating ocular vascular proliferative diseases

Publications (2)

Publication Number Publication Date
JP2015528454A true JP2015528454A (ja) 2015-09-28
JP2015528454A5 JP2015528454A5 (OSRAM) 2016-11-24

Family

ID=49083670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529009A Pending JP2015528454A (ja) 2012-08-28 2013-08-28 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用

Country Status (4)

Country Link
US (1) US20150297675A1 (OSRAM)
EP (1) EP2890389A1 (OSRAM)
JP (1) JP2015528454A (OSRAM)
WO (1) WO2014033184A1 (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501687A (ja) * 2015-11-18 2019-01-24 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
JP2019504882A (ja) * 2016-01-26 2019-02-21 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆアンタゴニストの液体製剤
JP2021503472A (ja) * 2017-11-20 2021-02-12 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
JP2021509912A (ja) * 2018-03-16 2021-04-08 ノバルティス アーゲー 眼疾患を治療するための方法
JP2024038137A (ja) * 2015-12-30 2024-03-19 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
WO2014203183A1 (en) * 2013-06-20 2014-12-24 Novartis Ag Use of a vegf antagonist in treating macular edema
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
WO2017117512A2 (en) 2015-12-30 2017-07-06 Marshall University Research Corporation Compositions and methods for treating retinopathy
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
KR102038008B1 (ko) * 2018-04-03 2019-10-29 주식회사 루트로닉 안과용 치료장치 및 이의 제어방법
CN120058958A (zh) 2018-09-24 2025-05-30 视点制药公司 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
AU2020344685A1 (en) * 2019-09-13 2022-04-14 Aldeyra Therapeutics, Inc. Ophthalmic formulations of methotrexate
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CA3183808A1 (en) 2020-06-11 2021-12-16 Genentech, Inc. Nanolipoprotein-polypeptide conjugates and compositions, systems, and methods using same
WO2023019216A2 (en) * 2021-08-13 2023-02-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating ischemic eye disease
US11911385B1 (en) 2022-12-14 2024-02-27 Aldeyra Therapeutics, Inc. Methotrexate treatment methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530484A (ja) * 2002-02-07 2005-10-13 デルタ バイオテクノロジー リミテッド アルブミン融合抗血管形成ペプチド
JP2011526892A (ja) * 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399612B2 (en) * 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2010060748A1 (en) * 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
WO2010136492A2 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
WO2012105610A1 (ja) * 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530484A (ja) * 2002-02-07 2005-10-13 デルタ バイオテクノロジー リミテッド アルブミン融合抗血管形成ペプチド
JP2011526892A (ja) * 2008-06-30 2011-10-20 アンジオブラスト システムズ，インコーポレーテッド 併用療法を使用した眼疾患及び過剰血管新生の治療

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOLECULAR VISION, vol. 11, JPN6017019849, 2011, pages 797 - 803, ISSN: 0003708337 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019501687A (ja) * 2015-11-18 2019-01-24 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
JP2022177129A (ja) * 2015-11-18 2022-11-30 フォーマイコン アーゲー Ｖｅｇｆ拮抗薬を収容したプレフィルドプラスチックシリンジ
JP2024038137A (ja) * 2015-12-30 2024-03-19 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
JP2019504882A (ja) * 2016-01-26 2019-02-21 フォーマイコン アーゲーＦｏｒｍｙｃｏｎ Ａｇ Ｖｅｇｆアンタゴニストの液体製剤
JP2021503472A (ja) * 2017-11-20 2021-02-12 ジャスト−エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
JP7183268B2 (ja) 2017-11-20 2022-12-05 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド 等張化剤としてリジン塩を含有するアフリベルセプト製剤及びその使用
JP2021509912A (ja) * 2018-03-16 2021-04-08 ノバルティス アーゲー 眼疾患を治療するための方法
JP2021191778A (ja) * 2018-03-16 2021-12-16 ノバルティス アーゲー 眼疾患を治療するための方法
JP2024042697A (ja) * 2018-03-16 2024-03-28 ノバルティス アーゲー 眼疾患を治療するための方法

Also Published As

Publication number Publication date
US20150297675A1 (en) 2015-10-22
EP2890389A1 (en) 2015-07-08
WO2014033184A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
JP2015528454A (ja) 眼血管増殖性疾患の処置におけるｖｅｇｆアンタゴニストの使用
RU2676274C2 (ru) Применение антагониста vegf при лечении хориоретинальных неоваскулярных нарушений и нарушений проницаемости у педиатрических пациентов
JP2016522249A (ja) 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
Costa et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study
CA2718161C (en) Drug delivery to the anterior and posterior segments of the eye using eye drops
TW202202138A (zh) 含有酪胺酸激酶抑制劑之眼用植入物
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
JP2016522250A (ja) 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用
JP2016523956A (ja) 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用
KR102373289B1 (ko) 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도
WO2014203181A1 (en) Treatment of polypoidal choroidal vasculopathy
CA3149706A1 (en) Methods for treating ocular diseases
SARIREH et al. Intravitreal Bevacizumab Alone Versus Combined Bevacizumab and Macular Grid Laser Photocoagulation in Diffuse Diabetic Macular Oedema.
US20230167170A1 (en) Compositions comprising anti-vegf and nanoparticles and methods of using the same for the treatment of abnormal or excessive angiogenesis
Ansari et al. Diabetic Eye Diseases
Theodoropoulou et al. Current trends in the treatment of diabetic macular edema
Yazdani et al. Intravitreal Bevacizumab (Avastin) Injection for Neovascular Glaucoma
Jiwani et al. Recent Trends in the Treatment of Diabetic Retinopathy: A
EDEMA 7B Diabetic Macular Edema: Clinical Trials

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170905

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109